Join Chris Wigley, CEO of Genomics England, for discussions about all things genomics.
Professor Robert Weinberg: Why do we get cancer?
"Mutations are the price that all animals must pay, starting with jellyfish all the way up to us humans"
Today on The G Word, Parker Moss, our Chief Commercial Officer is joined by Professor Robert (Bob) Weinberg. Professor Weinberg is a founding member of the Whitehead Institute for Biomedical Research and is a well-respected Professor in the MIT Department of Biology. He is the author of the legendary paper, the Hallmarks of Cancer, which was one of the most cited papers on life sciences of all time, and still provides us with much of the language of modern cancer biology.
They discuss why cancer occurs, why it spreads, the challenges and the hopes for early detection, and how research is contributing to improving survival for patients around the world.
Prof Kate Tatton Brown: Knowledge is Changing The World of Healthcare As We Know It
"We need to think about Genomics and we need to think about education because both are going to massively, massively change, and improve. I think we will be living in a very different space [in 30 years] than we are now...we are at the tip of the Iceberg."
In this episode of The G Word, our CEO Chris Wigley is joined by Professor Kate Tatton Brown who is the Clinical Director and Head of the Genomics Education Programme at Health Education England. She's also a consultant in clinical genetics at St. George's University Hospital, and a Professor in clinical genetics and genomics education with St. George's, within the University of London.
Together, they discuss Kate's pursuit of education for others around the complex topics of genomic medicine and research. Delving into the fundamentals of undergraduate and postgraduate curriculum changes, NHS involvement in genomic healthcare and the necessity of moving forward within research. They also discuss the importance of genomic awareness, access to testing and their project GeNotes - genomic notes for clinicians.
Nadeem Sarwar: Drug discovery: why do Pharma want my data?
"...the insights we get from human genetics truly are a gift from nature..."
On today's episode of The G Word, Parker Moss, our Chief of Ecosystems and Partnership Officer, is joined by Nadeem Sarwar, the Global Head of Genomic Strategies and Global Head of Digital Therapeutics (DTx) Strategies at Eisai.
They discuss the difference between associations and drivers of disease, the importance of knockouts and the benefits of having insights through our DNA. They also discuss the phenomenon of making medicine, how quickly we can change/have changed the realm of medicine and the possibilities of the future.
Fireside Chat with Daphne Koller, insitro: Machine Learning and Multimodal Data in Drug Discovery
“We are now in a world where there is this an abundance of data, which is only the beginning to what we're likely to be able to see in the coming years. At the same time, we have this incredible set of machine learning methods [...]. This seems to be a moment in time when those two tidal waves are about to come together in a way that offers us the opportunity to unlock some of the underlying secrets and complexities that underlie human health and human disease.”
This week we are sharing for posterity the discussion that Parker Moss, our Chief Commercial Officer, hosted earlier this month at the Genomics England Research Summit. Parker’s discussion was with the world renowned Daphne Koller, the founder and CEO of insitro.
Parker and Daphne explored the use of AI and machine learning in drug discovery and discussed the value of multimodal analysis. They also touched on some of the challenges of causal inference and target validation with unsupervised machine learning methodologies. Parker and Daphne then discussed the recent partnership between Genomics England and insitro.
Dr Genya Dana: The Power of Genomics
“What will be important is to engage with the patient community, it will be a very important process to complement the science that we are doing and to engage with those ultimate end users. That is the beauty of having these conversations with the people who are going to eventually end up adopting the technology.”
Today's episode of The G Word is a little different. We are sharing a live recording of a recent discussion at the Public Policy Projects Global Genomics Conference between Chris Wigley, our CEO, and Dr Genya Dana, Global Head of Health Policy at Avellino.
In their conversation, they delved into all things policy, such as data, ethics and education as genomics comes into the mainstream of healthcare and society. They also discussed the importance of engaging with the participant community and Dr Genya Dana’s work in the Precision Medicine Department at the World Economic Forum.
Professor, Sir Munir Pirmohamed: Disease, Drugs and Genomes
"If we had the same immune system, all of us, then we would be extinct by now"
On todays episode of The G Word, our CEO, Chris Wigley, is joined with Professor, Sir Munir Pirmohamed, a British clinical pharmacologist and geneticist. Munir is also the NHS chair of Pharmacogenomics at the University of Liverpool.
They discuss the importance of pharmaceutical drug development, understanding genome structures to better identify and predict diseases and how our lifestyle choices can lead to variation in how our genes interact with drugs. They also delve into the complexity of pharmacogenomic decisions, discussing, taking into account both clinical and genomic factors.